Suggested remit - To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating progressive fibrosing interstitial lung disease (PF-ILD).
Status Proposed
Process STA 2018
ID number 1599

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
08 November 2019 (14:00) Scoping workshop (Manchester)
23 September 2019 - 21 October 2019 Appraisal consultation
27 August 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of nintedanib for treating progressive fibrosing interstitial lung disease ID1599. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. On receiving information from the company that markets nintedanib, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 13 September 2019 will be cancelled. We apologise for any inconvenience this may cause. The Scoping workshop will be rescheduled to November 2019. If you have any comments or concerns, please contact the project manager for this proposed appraisal Michelle Adhemar via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance